Rare Disease Day 2015: How Rare Disease is Shaping the Future of Healthcare

Today is Rare Disease Day 2015, an international advocacy day to focus on the daily lives of patients, families and caregivers who are living with a rare disease. Rare disease communities have been responsible for the reinvention of many aspects of our healthcare system are truly paving the way for precision medicine.

We Are All Zebras

A Potential Blood Test for Diagnosis of Alzheimer’s Disease

Researchers from Saarland University and Siemens Healthcare report that a new blood test can accurately discriminate between healthy people and patients with Alzheimer’s disease. It’s hoped the non-invasive and relatively cheap test could one day help with diagnosis. The research is published in the open access journal Genome Biology [2].

Alzheimer's disease

Dark Matter DNA Active in Brain During Day-Night Cycle

Long stretches of DNA once considered inert “dark matter” of the genome — the over 98% of DNA that doesn’t code for proteins — appear to be uniquely active in a part of the brain known to control the body’s 24-hour cycle, according to researchers at the National Institutes of Health. The findings appear in the August 14th edition of the journal Proceedings of the National Academy of Sciences [1].

Dark Matter DNA

F1000 Research Publishes First Articles

In February, the Faculty of 1000 (F1000) launched F1000 Research, an innovative, new open access publishing program for biology and medicine. Last week, F1000 announced the publication of F1000 Research’s first few articles [1].

F1000 Research

Biomarker Bulletin: February 7, 2011

Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.

Biomarker Commons
  • Prize4Life Awards $1 Million Prize for Discovery of ALS Biomarker

    Prize4Life, a non-profit organization dedicated to accelerating the discovery of a cure for Amyotrophic Lateral Sclerosis (ALS) by offering incentives to drive innovation, today announced that Dr. Seward Rutkove, Chief of the Division of Neuromuscular Disease at Beth Israel Deaconess Medical Center and Associate Professor of Neurology at Harvard Medical School, has received the $1 million dollar Prize4Life award for the discovery of a new ALS biomarker.

  • Rosetta Genomics Signs Agreements to Advance Development of Body Fluids-Based Diagnostic Tests

    Rosetta Genomics has announced that it has signed two new agreements for the development and validation of microRNA-based diagnostics for various indications related to its Gen 3 products. Rosetta Genomics Gen 3 tests focus on cardiovascular indications, neurodegenerative diseases, women’s health and early detection of certain cancers, and are designed to leverage microRNA biomarkers extracted from body fluids.

  • Genomic Health Announces Results of Biomarker Discovery Program Using Next-Generation Sequencing

    Last week, Genomic Health, Inc. announced that its scientists had successfully used Illumina next-generation sequencing technology to survey expression of the whole human transcriptome and test hypotheses for biomarker discovery in archived tumor and normal breast tissue samples.

  • Spinal Muscular Atrophy Foundation and Rules-Based Medicine Collaborate on SMA Biomarker Panel

    The Spinal Muscular Atrophy (SMA) Foundation and Rules-based Medicine (RBM) have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM’s Multi-Analyte Profiling (MAP) technology platform.

  • Computable Genomix Secures Investment for the Development of Genetic Biomarker Tests

    Memphis-based Computable Genomix announced this week that it has secured an investment from venture capital firm Innova Memphis to pilot a novel process for developing genetic biomarker tests. Leveraging its next-generation computational discovery capability, the company is developing highly targeted genetic biomarker tests for clinical researchers.